A phase III multicenter study of cytomegalovirus prophylaxis with valacyclovir [valaciclovir] for the prevention of serious fungal and bacterial infections among cytomegalovirus seronegative recipients of cytomegalovirus seropositive sx stem cell transplants
Phase of Trial: Phase III
Latest Information Update: 08 Apr 2009
At a glance
- Drugs Valaciclovir (Primary)
- Indications Bacterial infections; Cytomegalic inclusion disorders; Cytomegalovirus infections; Mycoses
- Focus Therapeutic Use
- 08 Apr 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 04 Dec 2007 New trial record.